João Santos

Dr. João Santos

Department of Biochemical and Pharmaceutical Technology, School of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo, SP, Brazil
orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 January 2019 in Frontiers in Bioengineering and Biotechnology
Verified
Journal Article
Open access
PDF file
LBLarissa Brumano
Larissa Brumano
FSFrancisco Vitor Santos da Silva
Francisco Vitor Santos da Silva
TCTales Alexandre Costa-Silva
Tales Alexandre Costa-Silva
AAAlexsandra Conceição Apolinário
Alexsandra Conceição Apolinário
João SantosJoão Santos
João Santos
Adalberto Pessoa-JrAdalberto Pessoa-Jr
Adalberto Pessoa-Jr
L-Asparaginase (ASNase) is a vital component of the first line treatment of acute lymphoblastic leukemia (ALL), an aggressive type of blood cancer expected to afflict over 53,000 people worldwide by 2020. More recently, ASNase has also been shown to have potential for preventing metastasis from solid tumors. The ASNase treatment is, however, characterized by a plethora of potential side effects, ranging from immune reactions to severe toxicity. Consequently, in accordance with Quality-by-Design (QbD) principles, ingenious new products tailored to minimize adverse reactions while increasing patient survival have been devised. In the following pages, the reader is invited for a brief discussion on the most recent developments in this field. Firstly, the review presents an outline of the recent improvements on the manufacturing and formulation processes, which can severely influence important aspects of the product quality profile, such as contamination, aggregation and enzymatic activity. Following, the most recent advances in protein engineering applied to the development of biobetter ASNases (i.e., with reduced glutaminase activity, proteolysis resistant and less immunogenic) using techniques such as site-directed mutagenesis, molecular dynamics, PEGylation, PASylation and bioconjugation are discussed. Afterwards, the attention is shifted toward nanomedicine including technologies such as encapsulation and immobilization, which aim at improving ASNase pharmacokinetics. Besides discussing the results of the most innovative and representative academic research, the review provides an overview of the products already available on the market or in the latest stages of development. With this, the review is intended to provide a solid background for the current product development and underpin the discussions on the target quality profile of future ASNase-based pharmaceuticals.

1 November 2014 in Fluid Phase Equilibria
Verified
Journal Article
Closed access
ABArijit Bhattacharjee
Arijit Bhattacharjee
ALAndreia Luís
Andreia Luís
João SantosJoão Santos
João Santos
José Lopes da SilvaJosé Lopes da Silva
José Lopes da Silva
Mara FreireMara Freire
Mara Freire
JCJoao Coutinho
Joao Coutinho

22 February 2022 in Journal of Materials Chemistry B
Verified
Journal Article
Closed access
PDF file
ASAmanda R. P. Silva
Amanda R. P. Silva
MGMarina S. Guimarães
Marina S. Guimarães
JRJheniffer Rabelo
Jheniffer Rabelo
LBLisandra Herrera Belén
Lisandra Herrera Belén
CPCaio José Perecin
Caio José Perecin
CRCARLOTA RANGEL-YAGUI
CARLOTA RANGEL-YAGUI
Antimicrobial peptides (AMPs) are ubiquitous host defense peptides characterized by their antibiotic activity and lower propensity for developing resistance compared to classic antibiotics. While several AMPs have shown activity against antibiotic-sensitive and even multi-drug resistant strains, some bottlenecks to further development and clinical applications are still present, for instance, low antimicrobial activity, instability under physiological conditions, systemic toxicity and the potential for compromising the innate host defense immunity. Conjugation to molecules such as proteins, synthetic polymers, small molecules and nanoparticles are strategies under investigation to boost the therapeutic efficacy of AMPs. This review focuses on the design and application of AMPs’ conjugates. In silico tools for creating new AMPs and AMPs’ conjugates and their clinical development are also discussed. Furthermore, key future considerations regarding the major achievements and challenges of AMPs’ conjugates in the antimicrobial resistance context are presented as a take-home message.

14 October 2014 in Biotechnology Progress
Verified
Journal Article
Closed access
PDF file
João SantosJoão Santos
João Santos
FSFrancisca A. e Silva
Francisca A. e Silva
SVSonia P. M. Ventura
Sonia P. M. Ventura
JCJoao Coutinho
Joao Coutinho
RSRanyere Lucena de Souza
Ranyere Lucena de Souza
Álvaro Silva LimaÁlvaro Silva Lima
Álvaro Silva Lima

11 October 2018 in ACS Sustainable Chemistry & Engineering
Verified
Journal Article
Closed access
João SantosJoão Santos
João Santos
JTJoão P. Trigo
João P. Trigo
&E& Eacute
& Eacute
LMLia Maricato
Lia Maricato
Cláudia NunesCláudia Nunes
Cláudia Nunes
ÉMÉlia Maricato
Élia Maricato

30 November 2017 in Journal of Chemical Technology & Biotechnology
Verified
Journal Article
Closed access
PDF file
João SantosJoão Santos
João Santos
JFJuan C Flores‐Santos
Juan C Flores‐Santos
GMGiovanna P. Meneguetti
Giovanna P. Meneguetti
CRCARLOTA RANGEL-YAGUI
CARLOTA RANGEL-YAGUI
JCJoao Coutinho
Joao Coutinho
Adalberto Pessoa-JrAdalberto Pessoa-Jr
Adalberto Pessoa-Jr